Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 2
1965 1
1981 1
1991 1
1992 1
1993 1
1998 2
2000 5
2001 1
2002 1
2003 3
2004 3
2005 10
2006 11
2007 8
2008 7
2009 11
2010 17
2011 9
2012 12
2013 22
2014 20
2015 30
2016 27
2017 27
2018 20
2019 28
2020 25
2021 19
2022 17
Text availability
Article attribute
Article type
Publication date

Search Results

298 results
Results by year
Filters applied: . Clear all
Page 1
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Jabbour E, et al. Among authors: yin cc. Lancet Oncol. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7. Epub 2015 Sep 30. Lancet Oncol. 2015. PMID: 26432046 Free PMC article. Clinical Trial.
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. Quesada AE, et al. Among authors: yin cc. Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7. Am J Hematol. 2019. PMID: 30963592 Free article. Clinical Trial.
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Zhao S, et al. Among authors: yin cc. Am J Hematol. 2020 Jun;95(6):623-629. doi: 10.1002/ajh.25796. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32239765 Free article. Clinical Trial.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M; Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Wang ML, et al. Among authors: yin cc. Lancet Oncol. 2022 Mar;23(3):406-415. doi: 10.1016/S1470-2045(21)00638-0. Epub 2022 Jan 21. Lancet Oncol. 2022. PMID: 35074072 Clinical Trial.
A transcriptional regulatory module controls lipid accumulation in soybean.
Lu L, Wei W, Li QT, Bian XH, Lu X, Hu Y, Cheng T, Wang ZY, Jin M, Tao JJ, Yin CC, He SJ, Man WQ, Li W, Lai YC, Zhang WK, Chen SY, Zhang JS. Lu L, et al. Among authors: yin cc. New Phytol. 2021 Jul;231(2):661-678. doi: 10.1111/nph.17401. Epub 2021 May 25. New Phytol. 2021. PMID: 33864683 Free article.
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Jain P, et al. Among authors: yin cc. Am J Hematol. 2021 May 1;96(5):E137-E140. doi: 10.1002/ajh.26109. Epub 2021 Feb 11. Am J Hematol. 2021. PMID: 33491779 Free article. No abstract available.
MYC/BCL2 double-hit high-grade B-cell lymphoma.
Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ. Li S, et al. Among authors: yin cc. Adv Anat Pathol. 2013 Sep;20(5):315-26. doi: 10.1097/PAP.0b013e3182a289f2. Adv Anat Pathol. 2013. PMID: 23939148 Review.
298 results